These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 21128112)
1. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance. Skildum A; Dornfeld K; Wallace K Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112 [TBL] [Abstract][Full Text] [Related]
2. Troglitazone Stimulates Cancer Cell Uptake of 18F-FDG by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction. Moon SH; Lee SJ; Jung KH; Quach CH; Park JW; Lee JH; Cho YS; Lee KH J Nucl Med; 2016 Jan; 57(1):129-35. PubMed ID: 26449833 [TBL] [Abstract][Full Text] [Related]
3. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665 [TBL] [Abstract][Full Text] [Related]
5. [Troglitazone sensitizes effect of epirubicin on breast cancer cells]. Sun JX; Meng ZX; Lv JH; Sun YJ Ai Zheng; 2006 Aug; 25(8):960-6. PubMed ID: 16965675 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells. Soller M; Dröse S; Brandt U; Brüne B; von Knethen A Mol Pharmacol; 2007 Jun; 71(6):1535-44. PubMed ID: 17325128 [TBL] [Abstract][Full Text] [Related]
7. Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects. Pseftogas A; Gonidas C; Mosialos G Int J Biochem Cell Biol; 2017 Jan; 82():49-56. PubMed ID: 27865894 [TBL] [Abstract][Full Text] [Related]
8. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells. Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218 [TBL] [Abstract][Full Text] [Related]
9. Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. Rashid-Kolvear F; Taboski MA; Nguyen J; Wang DY; Harrington LA; Done SJ BMC Cancer; 2010 Jul; 10():390. PubMed ID: 20650001 [TBL] [Abstract][Full Text] [Related]
10. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439 [TBL] [Abstract][Full Text] [Related]
11. Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells. Park BH; Lee SB; Stolz DB; Lee YJ; Lee BC J Biol Chem; 2011 Jun; 286(22):20087-99. PubMed ID: 21467033 [TBL] [Abstract][Full Text] [Related]
12. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells. Ponnusamy L; Mahalingaiah PKS; Singh KP Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002 [TBL] [Abstract][Full Text] [Related]
13. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand. Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441 [TBL] [Abstract][Full Text] [Related]
14. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. Yu HN; Noh EM; Lee YR; Roh SG; Song EK; Han MK; Lee YC; Shim IK; Lee SJ; Jung SH; Kim JS; Youn HJ Biochem Biophys Res Commun; 2008 Dec; 377(1):242-7. PubMed ID: 18835379 [TBL] [Abstract][Full Text] [Related]